References
- http://www.alsuntangled.com/open.php. Accessed June 1, 2015.
- Nelson S, Bose S, Grunwald G, Myhill P, McCord J. The induction of superoxide dismutase and catalase in vivo: a fundamentally new approach to antioxidant therapy. Free Radical Biology & Medicine. 2006;40:341–7.
- Velmurugan K, Alam J, McCord J, Pugazhenthi S. Synergic induction of heme oxygenase-1 by they antioxidant supplement Protandim. Free Radical Biology and Medicine. 2009;46:430–40.
- Gao B, Doan A, Hybertson B. The clinical potential of influencing Nrf2 signaling in degenerative and immunological disorders. Clinical Pharmacology: Advances and Applications. 2014;6:19–34.
- Barber S, Shaw P. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radical Biology & Medicine. 2010;48:629–41.
- Sarlette A, Krampfl K, Grothe C, Neurhoff N, Dengler R, Petri S. Nuclear erythroid 2-related factor 2-anti-oxidative response element signaling pathway in motor cortex and spinal cord in amyotrophic lateral sclerosis. J Neuropath and Exp Neurol. 2008;67:1055–62.
- Bergstrom P, von Otter M, Nilsson A, Nilsson M, Andersen P, Hammersten O, Zetterberg H. Association of NFE2L2 and KEAP1 haplotypes with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:130–7.
- Donovan E, McCord JM, Reuland DJ, Miller BF, Hamilton KL. Phytochemical activation of Nrf2 protects human coronary endothelial cells against an oxidative challenge. Oxid Med Cell Longev. 2012;2012:132931.
- Jiminez-Osorio A, Picazo A, Gonzalez-Reyes S, Barrera-Oviedo D, Rodriguez-Arellano M, Pedraza-Chaverri J. Nrf2 and redox status in prediabetic and diabetic patients. Int J Mol Sci. 2014;15:20290–305.
- http://globenewswire.com/news-release/2013/06/25/556132/10037495/en/Dr-Joe-McCord-LifeVantage-Corporation-s-First-Chief-Science-Officer-Retires-From-Company.html. Accessed August 8, 2015.
- Neymotin A, Calingsan N, Willie E, Naseri M, Petri S, Damiano M, et al. Neuroprotective effect of Nrf2/ARE activators, CDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis. Free Radical Biology and Medicine. 2011;51:88–96.
- Guo Y, Zhang K, Wang Q, Li Z, Yin Y, Xu Q, et al. Neuroprotective effects of diallyl trisulfide in SOD1-G93A transgenic mouse model of amyotrophic lateral sclerosis. Brain Res. 2011;1374:110–15.
- Tanaka K, Kanno T, Yamgisawa Y, Yasutake K, Inoue S, Hirayama N, Ikeda JE. A novel acylaminoimidazole derivative, WN1316, alleviates disease progression via suppression of glial inflammation in ALS mouse model. PLoS One. 2014;31:e9.
- Guo Y, Zhang Y, Wen D, Duan Wm An T, Shi P, Want J, et al. The modest impact of transcription factor Nrf2 on the course of disease in an ALS animal model. Laboratory Investigation. 2013;93:825–33.
- Vargas M, Johnson D, Sirkis D, Messing A, Johnson J. Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. J Neurosci. 2008;28:13574–81.
- Vargas MR, Burton NC, Kutzke J, Gan L, Johnson D, Schafer M, et al. Absence of Nrf2 or its selective overexpression in neurons and muscle does not affect survival in ALS-lined mutant hSOD1 mouse models. PLoS One. 2013;8:e56625.
- Ludolph A, Bendotti C, Blaugrund E, Chio A, Greensmith L, Loeffler J, et al . Guidelines for preclinical animal research in ALS/MND: a consensus meeting. Amyotroph Lateral Scler. 2010;11:38–45.
- https://www.patientslikeme.com/als/patients/treatment/722-protandim-side-effects-and-efficacy#overview. Accessed August 6, 2015.
- https://alsliving.wordpress.com. Accessed July 6, 2015.
- Emails between Steven Bishop and ALSUntangled, July and August 2015.
- Belsh J. ALS diagnostic criteria of El Escorial revisited: do they meet the needs of clinicians as well as researchers? Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;(Suppl 1):S57–60.
- http://www.docmarvin.com/dr-marvin-bio/. Accessed August 6, 2015.
- Telephone call between N.orman Marvin and ALSUntangled, August 5, 2015.
- http://www.protandimscams.com/steven-and-jennifer-bishop-make-illegal-medical-claims-about-protandim-and-als/. Accessed August 6, 2015.
- Tsai C, Ho H, Yen D, Wang V, Lin K, Liao K, et al. Reversible motor neuron disease. Eur Neurol. 1993;33:387–9.
- Tucker T, Layzer R, Miller R, Chad D. Subacute reversible motor neuron disease. Neurology. 1991;41:1541–4.
- https://www.lifevantage.com/company/. Accessed August 6, 2015.
- Burnham E, McCord J, Swapan B, Brown L, House R, Moss M, et al. Protandim does not influence alveolar epithelial permeability or intrapulmonary oxidative stress in human subjects with alcohol use disorders. American Journal of Physiology-Lung Cellular and Molecular Physiology. 2012;302:L688–99.
- Bunton-Stasyshyn R, Sacon R, Fratta P, Fisher E. SOD1 function and its implications for amyotrophic lateral sclerosis pathology. Neuroscientist. 2014; Dec 9: Epub ahead of print.